Combined Modality Therapy

FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma

2 months ago talkbio0Tagged Adcetris, Antibody-Drug Conjugates, Approved, BRENTUXIMAB, Combined Modality Therapy, Diffuse Large B-Cell Lymphoma, LBCL, Pfizer, United States Food and Drug Administration, vedotin

Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

3 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial

4 months ago talkbio0Tagged AstraZeneca, Combined Modality Therapy, J&J, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Rybrevant, survival trial, Tagrisso

J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

4 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm

6 months ago talkbio0Tagged biopharmaceutical industry, Combined Modality Therapy, inhibitors, Malignant Neoplasms, PD-1/PD-L1, Public Listing, Vascular Endothelial Growth Factor A

PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing

Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma

7 months ago talkbio0Tagged Approved, Combined Modality Therapy, first-line, isatuximab, Multiple Myeloma, sanofi, Sarclisa, United States Food and Drug Administration, VRd

Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.

Merck’s Keytruda-Lenvima Combination Shows Promise in Liver Cancer Treatment

7 months ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, Eisai, Keytruda, Lenvima, Liver and Intrahepatic Biliary Tract Carcinoma, Liver carcinoma

Keytruda, Lenvima, liver cancer, hepatocellular carcinoma, combination therapy, Merck, Eisai, clinical trials.

Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer

7 months ago talkbio0Tagged Combined Modality Therapy, first-line, LAG-3/PD-1, Malignant neoplasm of lung, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

7 months ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

8 months ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient